Literature DB >> 12385501

Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy.

Paul Shapiro1.   

Abstract

The mitogen-activated protein (MAP) kinase pathways represent several families of signal transduction cascades that mediate information provided by extracellular stimuli. MAP kinase pathways regulate a wide range of physiological responses, including cell proliferation, apoptosis, cell differentiation, and tissue development. Constitutive activation of MAP kinase proteins in experimental models has been shown to cause cell transformation and is implicated in tumorigenesis. Of clinical importance, MAP kinase pathways are regulated by Ras G-proteins, which are found to be mutated and constitutively active in approximately 30% of all human cancers. Thus, a major goal in the treatment of cancer is the development of specific compounds that target Ras and critical downstream signaling proteins responsible for uncontrolled cell growth. A variety of biochemical, molecular, and structural approaches have been used to develop drug compounds that target signaling proteins important for MAP kinase pathway activation. These compounds have been useful tools for identifying the mechanisms of MAP kinase pathway signaling and hold promise for clinical use. This review will present an overview of the major proteins involved in Ras and MAP kinase signaling pathways and their function in regulating cell cycle events and proliferation. In addition, some of the relevant compounds that have been developed to inhibit the activities of these proteins and MAP kinase signaling are discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12385501     DOI: 10.1080/10408360290795538

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  35 in total

1.  Hepatocyte transformation and tumor development induced by hepatitis C virus NS3 c-terminal deleted protein.

Authors:  Qiong-Qiong He; Rui-Xue Cheng; Yi Sun; De-Yun Feng; Zhu-Chu Chen; Hui Zheng
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Molecular imaging of drug-modulated protein-protein interactions in living subjects.

Authors:  Ramasamy Paulmurugan; Tarik F Massoud; Jing Huang; Sanjiv S Gambhir
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

3.  The time course of Akt and ERK activation on XIAP expression in HEK 293 cell line.

Authors:  Mousa Abkhezr; Ali Reza Keramati; Seyed Nasser Ostad; Jamshid Davoodi; Mohammad H Ghahremani
Journal:  Mol Biol Rep       Date:  2009-08-02       Impact factor: 2.316

4.  The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma.

Authors:  Savita Bhalla; Andrew M Evens; Bojie Dai; Sheila Prachand; Leo I Gordon; Ronald B Gartenhaus
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

5.  Inhibition of protein-protein interactions with low molecular weight compounds.

Authors:  Marilyn M Matthews; David J Weber; Paul S Shapiro; Andrew Coop; Alexander D Mackerell
Journal:  Curr Trends Med Chem       Date:  2008-01-01

6.  MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

Authors:  Julie Halkein; Sebastien P Tabruyn; Melanie Ricke-Hoch; Arash Haghikia; Ngoc-Quynh-Nhu Nguyen; Michaela Scherr; Karolien Castermans; Ludovic Malvaux; Vincent Lambert; Marc Thiry; Karen Sliwa; Agnes Noel; Joseph A Martial; Denise Hilfiker-Kleiner; Ingrid Struman
Journal:  J Clin Invest       Date:  2013-04-24       Impact factor: 14.808

7.  A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.

Authors:  Akiyoshi Kasuga; Kazuhiko Nakagawa; Fumio Nagashima; Toshio Shimizu; Daisuke Naruge; Shinichi Nishina; Hiroshi Kitamura; Takayasu Kurata; Atsuko Takasu; Yasuhito Fujisaka; Wataru Okamoto; Yuichiro Nishimura; Akihira Mukaiyama; Hideki Matsushita; Junji Furuse
Journal:  Invest New Drugs       Date:  2015-08-12       Impact factor: 3.850

8.  The resveratrol analogue 3,5,3',4',5'-pentahydroxy-trans-stilbene inhibits cell transformation via MEK.

Authors:  Ki Won Lee; Nam Joo Kang; Evgeny A Rogozin; Sang-Muk Oh; Yong Seok Heo; Angelo Pugliese; Ann M Bode; Hyong Joo Lee; Zigang Dong
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

9.  Using Caenorhabditis elegans as a model organism for evaluating extracellular signal-regulated kinase docking domain inhibitors.

Authors:  Fengming Chen; Alexander D Mackerell; Yuan Luo; Paul Shapiro
Journal:  J Cell Commun Signal       Date:  2008-12-23       Impact factor: 5.782

10.  Identification and expression analysis of ras gene in silkworm, Bombyx mori.

Authors:  Takehiko Ogura; Anjiang Tan; Takuya Tsubota; Takayo Nakakura; Takahiro Shiotsuki
Journal:  PLoS One       Date:  2009-11-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.